Back to search results

Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria

Abroad (travel likely)RecruitingPHASE2

Conditions

Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Ziaderm Research LLC, North Miami Beach, Florida, United States

    Contact: Study coordinator (Katelyn Louis) · katelyn@sullivandermatology.com · +1 305 652 8600
    Contact: Principal Investigator (Tory Sullivan)

  • Endeavor Health, Glenview, Illinois, United States

    Contact: Study coordinator (Alba Berty) · alba.berty@endeavorhealth.org
    Contact: Principal Investigator (Giselle Mosnaim)

  • Novartis Investigative Site, Grenoble, France

  • Novartis Investigative Site, Montpellier, France

  • Novartis Investigative Site, Paris, France

  • Novartis Investigative Site, Pierre-Bénite, France

  • Novartis Investigative Site, Dresden, Saxony, Germany

  • Novartis Investigative Site, Berlin, Germany

  • Novartis Investigative Site, Mainz, Germany

  • Novartis Investigative Site, Tübingen, Germany

  • Novartis Investigative Site, Poznan, Poland

  • Novartis Investigative Site, Rzeszów, Poland

  • Novartis Investigative Site, Warsaw, Poland

  • Novartis Investigative Site, Barcelona, Catalonia, Spain

  • Novartis Investigative Site, Pamplona, Navarre, Spain

  • Novartis Investigative Site, Alicante, Spain

  • Novartis Investigative Site, Madrid, Spain

View source on ClinicalTrials.gov(opens in a new tab)